FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089708758> ?p ?o ?g. }

• W3089708758 endingPage "161" @default.
• W3089708758 startingPage "154" @default.
• W3089708758 abstract "PD-L1 is a tumor ligand that binds to the PD-1 receptor on immune cells, thereby inhibiting the antitumor immune response. The antibody nivolumab is a PD-1 inhibitor, Food and Drug Administration approved for systemic treatment of several aggressive cancer types. Topically applied nivolumab may hold potential as a future strategy to treat keratinocyte cancer, but its molecular properties preclude unassisted topical uptake. The aim of this study was to investigate uptake and biodistribution of topically delivered nivolumab, assisted by two physical enhancement techniques with different delivery kinetics; ablative fractional laser (AFL) and electronically controlled pneumatic injection (EPI).In vitro porcine skin was exposed to CO2 AFL (20 mJ/mb, 5% density), followed by passive diffusion of nivolumab in a Franz cell (1 mg/ml, 18 hours, n = 6) or treated with EPI (4 bar) for immediate delivery of nivolumab (1 mg/ml, 10 minutes, n = 6). The resulting nivolumab skin concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) at three skin depths (100, 500, and 1500 µm), comparing the uptake from assisted delivery with intact skin. Biodistribution of nivolumab in the skin for all interventions was visualized by laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) and fluorescence microscopy.Delivery of nivolumab by AFL-assisted passive diffusion and immediate EPI both resulted in significantly enhanced uptake of nivolumab in all skin depths compared with intact skin (P < 0.05). With AFL, nivolumab concentrations reached 86.3 µg/cm3 (100 µm), 105.8 µg/cm3 (500 µm), and 19.3 µg/cm3 (1500 µm), corresponding to 2-10% of the applied concentration, with the highest deposition in the mid dermis. Immediate EPI delivered 429.4 µg/cm3 (100 µm), 584.9 µg/cm3 (500 µm), and 295.9 µg/cm3 (1500 µm) into the skin, corresponding to 29-58% of the applied nivolumab concentration. From qualitative visualization of the biodistribution, it appeared that nivolumab distributed in a horizontal and continuous homogenous band in the upper and mid dermis through AFL-exposed skin, whereas EPI-delivery showed a deep focal deposition extending into the deep dermis.AFL-assisted passive diffusion and immediate EPI-assisted delivery show the potential to deliver therapeutic antibodies locally. Future in vivo and pharmacokinetic studies would reveal the full potential for topical antibody delivery by energy-based devices. Lasers Surg. Med. © 2020 Wiley Periodicals LLC." @default.
• W3089708758 created "2020-10-08" @default.
• W3089708758 creator A5023282576 @default.
• W3089708758 creator A5035007833 @default.
• W3089708758 creator A5072053497 @default.
• W3089708758 creator A5083229695 @default.
• W3089708758 creator A5086669701 @default.
• W3089708758 creator A5088628110 @default.
• W3089708758 date "2020-09-30" @default.
• W3089708758 modified "2023-09-26" @default.
• W3089708758 title "Topical Delivery of Nivolumab, a Therapeutic Antibody, by Fractional Laser and Pneumatic Injection" @default.
• W3089708758 cites W1977035271 @default.
• W3089708758 cites W1984846619 @default.
• W3089708758 cites W2024862045 @default.
• W3089708758 cites W2081592601 @default.
• W3089708758 cites W2104347254 @default.
• W3089708758 cites W2156353875 @default.
• W3089708758 cites W2266633028 @default.
• W3089708758 cites W2278262184 @default.
• W3089708758 cites W2317334920 @default.
• W3089708758 cites W2346805382 @default.
• W3089708758 cites W2529484692 @default.
• W3089708758 cites W2535269087 @default.
• W3089708758 cites W2553767262 @default.
• W3089708758 cites W2580304990 @default.
• W3089708758 cites W2594305418 @default.
• W3089708758 cites W2784114001 @default.
• W3089708758 cites W2790574591 @default.
• W3089708758 cites W2791131840 @default.
• W3089708758 cites W2799372507 @default.
• W3089708758 cites W2884547661 @default.
• W3089708758 cites W2889412218 @default.
• W3089708758 cites W2893060838 @default.
• W3089708758 cites W2903116688 @default.
• W3089708758 cites W2908475938 @default.
• W3089708758 cites W2913633519 @default.
• W3089708758 cites W2913900454 @default.
• W3089708758 cites W2921515293 @default.
• W3089708758 cites W2980495364 @default.
• W3089708758 cites W2993728710 @default.
• W3089708758 cites W2994935162 @default.
• W3089708758 cites W2998604183 @default.
• W3089708758 cites W2998812710 @default.
• W3089708758 cites W2998989384 @default.
• W3089708758 cites W3009737145 @default.
• W3089708758 cites W3010839046 @default.
• W3089708758 cites W2763748436 @default.
• W3089708758 cites W2793630990 @default.
• W3089708758 doi "https://doi.org/10.1002/lsm.23322" @default.
• W3089708758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32997833" @default.
• W3089708758 hasPublicationYear "2020" @default.
• W3089708758 type Work @default.
• W3089708758 sameAs 3089708758 @default.
• W3089708758 citedByCount "8" @default.
• W3089708758 countsByYear W30897087582021 @default.
• W3089708758 countsByYear W30897087582022 @default.
• W3089708758 crossrefType "journal-article" @default.
• W3089708758 hasAuthorship W3089708758A5023282576 @default.
• W3089708758 hasAuthorship W3089708758A5035007833 @default.
• W3089708758 hasAuthorship W3089708758A5072053497 @default.
• W3089708758 hasAuthorship W3089708758A5083229695 @default.
• W3089708758 hasAuthorship W3089708758A5086669701 @default.
• W3089708758 hasAuthorship W3089708758A5088628110 @default.
• W3089708758 hasConcept C112705442 @default.
• W3089708758 hasConcept C159654299 @default.
• W3089708758 hasConcept C185592680 @default.
• W3089708758 hasConcept C202751555 @default.
• W3089708758 hasConcept C203014093 @default.
• W3089708758 hasConcept C2777701055 @default.
• W3089708758 hasConcept C2777807558 @default.
• W3089708758 hasConcept C2780030458 @default.
• W3089708758 hasConcept C55493867 @default.
• W3089708758 hasConcept C71924100 @default.
• W3089708758 hasConcept C8891405 @default.
• W3089708758 hasConcept C98274493 @default.
• W3089708758 hasConceptScore W3089708758C112705442 @default.
• W3089708758 hasConceptScore W3089708758C159654299 @default.
• W3089708758 hasConceptScore W3089708758C185592680 @default.
• W3089708758 hasConceptScore W3089708758C202751555 @default.
• W3089708758 hasConceptScore W3089708758C203014093 @default.
• W3089708758 hasConceptScore W3089708758C2777701055 @default.
• W3089708758 hasConceptScore W3089708758C2777807558 @default.
• W3089708758 hasConceptScore W3089708758C2780030458 @default.
• W3089708758 hasConceptScore W3089708758C55493867 @default.
• W3089708758 hasConceptScore W3089708758C71924100 @default.
• W3089708758 hasConceptScore W3089708758C8891405 @default.
• W3089708758 hasConceptScore W3089708758C98274493 @default.
• W3089708758 hasIssue "1" @default.
• W3089708758 hasLocation W30897087581 @default.
• W3089708758 hasLocation W30897087582 @default.
• W3089708758 hasOpenAccess W3089708758 @default.
• W3089708758 hasPrimaryLocation W30897087581 @default.
• W3089708758 hasRelatedWork W2045587037 @default.
• W3089708758 hasRelatedWork W2053638145 @default.
• W3089708758 hasRelatedWork W2066403337 @default.
• W3089708758 hasRelatedWork W2097980094 @default.
• W3089708758 hasRelatedWork W2165824272 @default.
• W3089708758 hasRelatedWork W2171197182 @default.

• next